Cadrenal Therapeutics Initiates Formal Strategic Process

Cadrenal Therapeutics announced its Board of Directors has initiated a formal strategic process to maximize the value of its orphan thrombo-inflammatory therapeutics. The company has retained Tungsten Advisors to lead this process.